Umirolimus
| Code | Size | Price |
|---|
| TAR-T26309-25mg | 25mg | £704.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26309-50mg | 50mg | £1,026.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T26309-100mg | 100mg | £1,564.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Umirolimus is a sirolimus derivative from a biodegradable polylactic acid polymer. It has enhanced anti-inflammatory and antiproliferative activity with an improved pharmacokinetic profile.
CAS:
851536-75-9
Formula:
C55H87NO14
Molecular Weight:
986.29
Purity:
0.98
SMILES:
CCOCCO[C@@H]1CC[C@H](C[C@H]1OC)C[C@H]([C@@H]2CC([C@@H](/C=C([C@H]([C@H](C([C@@H](C[C@@H](/C=C/C=C/C=C([C@@H](OC)C[C@@H]3CC[C@H]([C@@](O3)(C(C(N4CCCC[C@H]4C(O2)=O)=O)=O)O)C)C)C)C)=O)OC)O)C)C)=O)C
References
1. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carri? D, Naber C, Lipiecki J, Richardt G, I?iguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC; LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med. 2015 Nov 19;373(21):2038-47. doi: 10.1056/NEJMoa1503943. Epub 2015 Oct 14. PubMed PMID: 26466021.
2. Campos CM, Christiansen EH, Stone GW, Serruys PW. The EXCEL and NOBLE trials: similarities, contrasts and future perspectives for left main revascularisation. EuroIntervention. 2015;11 Suppl V:V115-9. doi: 10.4244/EIJV11SVA26. PubMed PMID: 25983143.
3. Lee JM, Cho DK, Hahn JY,et al. Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial. Am Heart J. 2016 Dec;182:1-8. doi: 10.1016/j.ahj.2016.07.022. Epub 2016 Aug 26. PubMed PMID: 27914488.
4. Buysschaert I, Verheye S. The Axxess stent. EuroIntervention. 2015;11 Suppl V:V143-4. doi: 10.4244/EIJV11SVA32. PubMed PMID: 25983150.